Drug Profile
Research programme: recombinant insulin lispro biosimilar - Biogenomics
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in India (SC, Injection)
- 16 Jan 2014 Research programme: recombinant insulin lispro biosimilar - Biogenomics is available for licensing in World as of 16 Jan 2014. http://www.biogenomics.co.in
- 14 Jan 2014 Preclinical trials in Diabetes mellitus in India (SC)